Accelrys, Inc. has announced that Gartner, Inc­. has rated the company's electronic laboratory notebooks (ELN) as "very high" or "high" in each scientific and functional domain in a recent report on considerations for selecting an ELN. Accelrys was the only vendor with ELNs that achieved those ratings in all categories.

The report, published Jan. 11, 2013 and titled "Manufacturers Must Consider Scientific Domain Expertise During ELN Selection," is based on insights collected by Gartner throughout hundreds of interviews, briefings and interactions with various clients. The Accelrys ELN secured a "very high" rating in chemistry, meaning the product is close to becoming a de facto standard in that category, as well as "high" ratings in biology, formulation, engineering, regulated environments and translational medicine. The Accelrys Laboratory Execution System was rated "very high" in regulated environments and "high" in formulation, while the Contur ELN rated "high" in chemistry.

"In the push to reduce innovation cycle times and share information among scientists and engineers, ELN technologies have the potential to be valuable tools, especially for transferring knowledge from ideas into product development," Gartner research director Michael Shanler said in the report. "However, as companies move toward "end-to-end" informatics solutions that extend from research into manufacturing, deep scientific functionality is often compromised when moving toward single solution providers. While IT often weights value for lower cost, simple governance and architecture simplicity, R&D sees deep scientific functionality as the primary criterion for sustaining innovation."

"With deep scientific domain experience and an integrated set of solutions for optimizing the lab-to-commercialization value chain – from research through downstream analytical development, quality control, quality assurance and manufacturing – Accelrys is proving that neither functionality nor expertise should be compromised in the quest to improve innovation," said Accelrys President and CEO Max Carnecchia. "We believe Gartner's 'high' and 'very high' ratings of our ELNs confirm our industry leading position in the market and our ability to deliver a breadth of solutions across scientific and functional domains for a diverse and global customer base."

RELATED ARTICLES

Genestack recently announced that they were joining the Milner Therapeutics Institute. In light of the announcement, I spoke to Prof. Tony Kouzarides, Director of the Milner Therapeutics Institute and Dr. Misha Kapushesky, Founder and CEO of Genestack, to learn more.

Today’s laboratories look very different to ten years ago, but what about ten years from now? When it comes to laboratory evolution, great strides have been made over the past decade, and further technological advancements are sure to bring us even closer to a fully automated ‘intelligent lab of the future’.

We’ve reached a significant point in time where the interest in Artificial Intelligence (AI), machine learning and deep learning have gained huge amounts of traction - why? We are moving into an era where science fiction is now becoming fact and reality.